WASHINGTON – The United States has officially agreed to cap tariffs on pharmaceutical imports from the European Union (EU) and Japan at a maximum of 15% following the conclusion of new trade agreements with the two major economic partners. The move, enacted by the Trump administration, is intended to create “reciprocal, fair, and balanced trade,” though it has sparked concerns among industry analysts about potential cost implications for American consumers.
The new trade framework with the EU dictates that the maximum duty applied to incoming pharmaceutical products will not exceed 15%. This established ceiling is a significant reduction from the initial punitive tariffs, which were threatened to be as high as 200% following earlier U.S. investigations into the national security risks posed by drug imports. European Commission President Ursula von der Leyen confirmed that the 15% rate is a “clear ceiling” with no further duties to be stacked on top.
Concurrently, the trade agreement with Japan also sets a general 15% tariff rate on imports. However, in a notable exception, the Trump administration signed an executive order specifically exempting generic pharmaceuticals, their active ingredients, and chemical precursors from this baseline tariff when imported from Japan.
The pharmaceutical industry has reacted cautiously to the development. While the 15% rate is lower than worst-case scenarios, analysts predict the new import costs could amount to billions of dollars annually, expenses that are highly likely to translate into higher prescription drug prices for patients in the U.S.
Trade bodies, including the European Federation of Pharmaceutical Industries and Associations (EFPIA), have consistently opposed the tariffs, arguing that imposing duties on medicines disrupts global supply chains and may ultimately discourage investment in U.S.-based research and development, counteracting the administration’s goal of strengthening domestic drug production.
Source : Click Here.